Jiangsu Hengrui Pharmaceuticals announced that its subsidiary, Suzhou Shengdiya Biomedical Co., Ltd., has had its injectable Rencan Qutuzumab included in the proposed breakthrough therapy list by the National Medical Products Administration's Drug Evaluation Center, with a public disclosure period of 7 days. This product has already received breakthrough therapy designation for six indications. In 2023, both the Chinese Society of Clinical Oncology and the National Comprehensive Cancer Network guidelines in the USA recommend that patients with platinum-resistant ovarian cancer participate in clinical trials. So far, approximately 0.715 billion yuan has been invested in the research and development of the injectable SHR-A1811 related projects.